Black Bird Biotech (Black Bird Biotech) Cash-to-Debt : 0.01 (As of Sep. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Black Bird Biotech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Black Bird Biotech's cash to debt ratio for the quarter that ended in Sep. 2023 was 0.01.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Black Bird Biotech couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for Black Bird Biotech's Cash-to-Debt or its related term are showing as below:

BBBT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 8.62
Current: 0.01

During the past 13 years, Black Bird Biotech's highest Cash to Debt Ratio was 8.62. The lowest was 0.00. And the median was 0.03.

BBBT's Cash-to-Debt is ranked worse than
97.42% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.94 vs BBBT: 0.01

Black Bird Biotech Cash-to-Debt Historical Data

The historical data trend for Black Bird Biotech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Black Bird Biotech Cash-to-Debt Chart

Black Bird Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

0.01

1.15

8.62

0.07

Black Bird Biotech Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial															0.10	0.07	0.01	0.01	0.01

Competitive Comparison of Black Bird Biotech's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Black Bird Biotech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Black Bird Biotech's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Black Bird Biotech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Black Bird Biotech's Cash-to-Debt falls into.

Black Bird Biotech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Black Bird Biotech's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.044	/	(0.67	+	0)
	=	0.07

Black Bird Biotech's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.006	/	(0.745	+	0.003)
	=	0.01

Black Bird Biotech (OTCPK:BBBT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Black Bird Biotech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Black Bird Biotech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Black Bird Biotech (Black Bird Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Black Bird Biotech Inc (OTCPK:BBBT) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

11961 Hilltop Road, Suite 22, Argyle, TX, USA, 76226

Website

https://www.blackbirdpotentials.com

Black Bird Biotech Inc is a licensed grower of industrial hemp under the Montana Hemp Pilot Program. In addition, it is the distributor in the U. S. and Canada for MiteXstream, an EPA-registered plant-based biopesticide effective in the eradication of spider mites, a pest that destroys crops, especially cannabis, hops, coffee, and house plants, as well as molds and mildew. Its products include MiteXstream Biopesticide, Grizzly Creek Naturals, and Black Bird American Hemp.

Executives

Jeffrey A Collins	director, 10 percent owner, officer: President	302 WASHINGTON ST., #513, SAN DIEGO CA 92103
Robert Edward Shea	director, 10 percent owner, officer: President, CEO, CFO, CAO	40 WARREN STREET, 3RD FLOOR, CHARLESTOWN MA 02129
John James Sutherland	director, 10 percent owner, officer: President, CEO, CFO & CAO	C/O SUITE 810 - 675 WEST HASTINGS STREET, VANCOUVER A1 V6B 1N2